Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer. One out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 13 points (0.1%) at 17,609 as of Tuesday, June 30, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,652 issues advancing vs. 1,385 declining with 154 unchanged. The Drugs industry currently sits up 1.7% versus the S&P 500, which is unchanged. Top gainers within the industry include bluebird bio ( BLUE), up 4.9%, Opko Health ( OPK), up 4.1%, Alnylam Pharmaceuticals ( ALNY), up 3.8%, Incyte ( INCY), up 2.2% and Illumina ( ILMN), up 1.7%. On the negative front, top decliners within the industry include AstraZeneca ( AZN), down 1.5%, Sanofi ( SNY), down 1.3%, GlaxoSmithKline ( GSK), down 1.1%, Novo Nordisk A/S ( NVO), down 0.6% and Novartis ( NVS), down 0.5%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Amgen ( AMGN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Amgen is up $0.78 (0.5%) to $152.38 on average volume. Thus far, 1.8 million shares of Amgen exchanged hands as compared to its average daily volume of 3.2 million shares. The stock has ranged in price between $151.51-$153.91 after having opened the day at $153.24 as compared to the previous trading day's close of $151.60. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. Amgen has a market cap of $120.1 billion and is part of the health care sector. Shares are down 0.8% year-to-date as of the close of trading on Monday. Currently there are 7 analysts who rate Amgen a buy, no analysts rate it a sell, and 8 rate it a hold. TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, revenue growth, reasonable valuation levels and expanding profit margins. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Amgen Ratings Report now. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.